Here the authors use genetic mutations to alter TCR signal strength and clonal selection of exhausted CD8+ T cells. They implicate CARD11 signaling as a sensor of this TCR signal strength and as a regulator of antitumor function in exhausted T cells that might be targeted to enhance cancer immunotherapies.